David Kaplan1, T Charles Casper2, C Gregory Elliott3, Shaohua Men4, Robert C Pendleton1, Larry W Kraiss5, Andrew S Weyrich6, Colin K Grissom7, Guy A Zimmerman1, Matthew T Rondina8. 1. Department of Internal Medicine, University of Utah, Salt Lake City. 2. Study Design and Biostatistics Center, University of Utah, Salt Lake City. 3. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Medical Center, Murray, UT. 4. Molecular Medicine Program, University of Utah, Salt Lake City. 5. Eccles Institute of Human Genetics, and the Division of Vascular Surgery, University of Utah, Salt Lake City. 6. Department of Internal Medicine, University of Utah, Salt Lake City; Molecular Medicine Program, University of Utah, Salt Lake City. 7. Department of Internal Medicine, University of Utah, Salt Lake City; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Medical Center, Murray, UT. 8. Department of Internal Medicine, University of Utah, Salt Lake City; Molecular Medicine Program, University of Utah, Salt Lake City. Electronic address: matthew.rondina@hsc.utah.edu.
Abstract
BACKGROUND: Prospective studies on the incidence of VTE during severe sepsis and septic shock remain absent, hindering efficacy assessments regarding VTE prevention strategies in sepsis. METHODS: We prospectively studied 113 consecutively enrolled patients in the ICU with severe sepsis and septic shock at three hospitals. All patients provided informed consent. VTE thromboprophylaxis was recorded for all patients. Patients underwent ultrasonography and were followed for VTE prior to ICU discharge. All-cause 28-day mortality was recorded. Variables from univariate analyses that were associated with VTE (including central venous catheter [CVC] insertion, age, length of stay, and mechanical ventilation) were included in a multivariable logistic regression analysis using backward stepwise elimination to determine VTE predictors. RESULTS: Mean APACHE (Acute Physiology and Chronic Health Evaluation) II score was 18.2 ± 7.0, and age was 50 ± 18 years. Despite all patients receiving guideline-recommended thromboprophylaxis, the incidence of VTE was 37.2% (95% CI, 28.3-46.8). Most VTE events were clinically significant (defined as pulmonary embolism, proximal DVT, and/or symptomatic distal DVT) and associated with an increased length of stay (18.2 ± 9.9 days vs 13.4 ± 11.5 days, P < .05). Mortality was higher in patients with acute VTE but did not reach statistical significance. Insertion of a CVC and longer mechanical ventilation duration were significant VTE risk factors. VTE incidence did not differ by thromboprophylaxis type. CONCLUSIONS: To our knowledge this is the first multicenter prospective study to identify a high incidence of VTE in patients with severe sepsis and septic shock, despite the use of universal, guideline-recommended thromboprophylaxis. Our findings suggest that the systemic inflammatory milieu of sepsis may uniquely predispose patients with sepsis to VTE. More effective VTE prevention strategies are necessary in patients with sepsis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02353910; URL: www.clinicaltrials.gov.
BACKGROUND: Prospective studies on the incidence of VTE during severe sepsis and septic shock remain absent, hindering efficacy assessments regarding VTE prevention strategies in sepsis. METHODS: We prospectively studied 113 consecutively enrolled patients in the ICU with severe sepsis and septic shock at three hospitals. All patients provided informed consent. VTE thromboprophylaxis was recorded for all patients. Patients underwent ultrasonography and were followed for VTE prior to ICU discharge. All-cause 28-day mortality was recorded. Variables from univariate analyses that were associated with VTE (including central venous catheter [CVC] insertion, age, length of stay, and mechanical ventilation) were included in a multivariable logistic regression analysis using backward stepwise elimination to determine VTE predictors. RESULTS: Mean APACHE (Acute Physiology and Chronic Health Evaluation) II score was 18.2 ± 7.0, and age was 50 ± 18 years. Despite all patients receiving guideline-recommended thromboprophylaxis, the incidence of VTE was 37.2% (95% CI, 28.3-46.8). Most VTE events were clinically significant (defined as pulmonary embolism, proximal DVT, and/or symptomatic distal DVT) and associated with an increased length of stay (18.2 ± 9.9 days vs 13.4 ± 11.5 days, P < .05). Mortality was higher in patients with acute VTE but did not reach statistical significance. Insertion of a CVC and longer mechanical ventilation duration were significant VTE risk factors. VTE incidence did not differ by thromboprophylaxis type. CONCLUSIONS: To our knowledge this is the first multicenter prospective study to identify a high incidence of VTE in patients with severe sepsis and septic shock, despite the use of universal, guideline-recommended thromboprophylaxis. Our findings suggest that the systemic inflammatory milieu of sepsis may uniquely predispose patients with sepsis to VTE. More effective VTE prevention strategies are necessary in patients with sepsis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02353910; URL: www.clinicaltrials.gov.
Authors: Deborah Cook; Mark Crowther; Maureen Meade; Christian Rabbat; Lauren Griffith; David Schiff; William Geerts; Gordon Guyatt Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: Elizabeth A Middleton; Jesse W Rowley; Robert A Campbell; Colin K Grissom; Samuel M Brown; Sarah J Beesley; Hansjörg Schwertz; Yasuhiro Kosaka; Bhanu K Manne; Krystin Krauel; Neal D Tolley; Alicia S Eustes; Li Guo; Robert Paine; Estelle S Harris; Guy A Zimmerman; Andrew S Weyrich; Matthew T Rondina Journal: Blood Date: 2019-07-31 Impact factor: 22.113
Authors: M Dietrich; C J Reuß; C Beynon; A Hecker; C Jungk; D Michalski; C Nusshag; K Schmidt; M A Weigand; M Bernhard; T Brenner Journal: Anaesthesist Date: 2020-01 Impact factor: 1.041
Authors: Andrea T Obi; Elizabeth Andraska; Yogendra Kanthi; Chase W Kessinger; Megan Elfline; Cathy Luke; Teruna J Siahaan; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: Thromb Haemost Date: 2016-12-15 Impact factor: 5.249
Authors: Mei Yang; Patrick B. Murphy; Laura Allen; Nathalie Sela; Shaylan Govind; Ken Leslie; Kelly Vogt Journal: Can J Surg Date: 2020-02-26 Impact factor: 2.089
Authors: Felipe Silva de França; Joel José Megale Gabrili; Laurence Mathieu; François Burgher; Joël Blomet; Denise V Tambourgi Journal: Arch Toxicol Date: 2021-01-04 Impact factor: 5.153
Authors: Ronit Mor-Cohen; Michal Zucker; Colin Grissom; Samuel M Brown; Uri Seligsohn; Robert A Campbell; Antoinette M Blair; Matthew T Rondina Journal: J Thromb Thrombolysis Date: 2019-02 Impact factor: 2.300